Research programme: CNS scarring therapeutics - Cotinga Pharmaceuticals
Latest Information Update: 10 Jan 2018
Price :
$50 *
At a glance
- Originator Critical Outcome Technologies; University of Western Ontario
- Developer Cotinga Pharmaceuticals; University of Western Ontario
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS trauma
Most Recent Events
- 08 Jan 2018 Critical Outcome Technologies is now called Cotinga Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for research development in CNS-trauma in Canada
- 12 Sep 2012 Early research in CNS trauma in Canada (unspecified route)